PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview: Allergic rhinitis • Understanding the disease • Classification of allergic rhinitis • Causes • Signs and symptoms • Risk factors • Diagnosis and testing • Treatment • Epidemiology • Economic burden and impact on quality of life PART 06: Pipeline analysis • Information on pipeline candidates • Clinical trial information of allergic rhinitis PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation based on class of drugs • Antihistamines • Intranasal corticosteroids • Immunotherapies • Global antihistamines drugs market • Global intranasal corticosteroids drugs market • Global immunotherapies drugs market PART 09: Market segmentation by route of administration • Oral • Parenteral • Intranasal PART 10: Market segmentation by dosage form • Solid • Liquid PART 11: Geographical segmentation • Global allergic rhinitis drugs market by geography 2015-2020 • Allergic rhinitis drugs market in Americas • Allergic rhinitis drugs market in EMEA • Allergic rhinitis drugs market in APAC PART 12: Market drivers • Increased prevalence of allergic rhinitis • Rise in awareness about allergic rhinitis • High usage of tobacco • Presence of high unmet medical needs PART 13: Impact of drivers PART 14: Market challenges • Increased preference for CAM • Patent expiries and competition from generic drugs • Adverse effects of drugs • Poor patient adherence PART 15: Impact of drivers and challenges PART 16: Market trends • Self-medication using OTC products • Increased R&D • Intense competition • Strategic alliances PART 17: Vendor landscape • Competitive scenario • Market share analysis 2015 • AstraZeneca • GlaxoSmithKline • Meda Pharmaceuticals • Merck • Sanofi • UCB • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of allergic rhinitis Exhibit 03: Risk factors associated with allergic rhinitis Exhibit 04: Major diagnostic procedures for allergic rhinitis Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis Exhibit 07: Non-pharmacological therapies for allergic rhinitis Exhibit 08: Examples of non-pharmacological therapies Exhibit 09: Treatment algorithm of allergic rhinitis Exhibit 10: Prevalence of allergic rhinitis in China Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio Exhibit 12: Allergic rhinitis clinical trials by development phase 2015 Exhibit 13: Allergic rhinitis clinical trials by trial status 2015 Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions) Exhibit 15: Five forces analysis Exhibit 16: Global allergic rhinitis market based on class of drugs Exhibit 17: Examples of prescription and OTC intranasal corticosteroids Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015 Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions) Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions) Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions) Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions) Exhibit 23: Global allergic rhinitis drugs market by route of administration Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form Exhibit 25: Global allergic rhinitis drugs market by geography 2015 Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions) Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions) Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions) Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions) Exhibit 30: Drivers of global allergic rhinitis drugs market Exhibit 31: Impact of drivers Exhibit 32: Challenges of global allergic rhinitis drugs market Exhibit 33: Impact of drivers and challenges Exhibit 34: Trends of global allergic rhinitis drugs market Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015 Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions) Exhibit 38: AstraZeneca: Business segmentation by revenue 2014 Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014 Exhibit 41: AstraZeneca: Key takeaways Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014 Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014 Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions) Exhibit 46: GlaxoSmithKline: Key takeaways Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014 Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions) Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014 Exhibit 50: Meda Pharmaceuticals: Top-selling drugs Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions) Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions) Exhibit 53: Meda Pharmaceuticals: Key takeaways Exhibit 54: Merck: Business segmentation by revenue 2014 Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 56: Merck: Geographical segmentation by revenue 2014 Exhibit 57: Merck: Top-selling drugs Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions) Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions) Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions) Exhibit 61: Merck: Key takeaways Exhibit 62: Sanofi: Business segmentation by revenue 2014 Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 64: Sanofi: Geographical segmentation by revenue 2014 Exhibit 65: Sanofi: Top-selling drugs Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions) Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions) Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions) Exhibit 69: Sanofi: Key takeaways Exhibit 70: UCB: Product segmentation by revenue 2014 Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions) Exhibit 72: UCB: Geographical segmentation by revenue 2014 Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions) Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions) Exhibit 75: UCB: Key takeaways

AstraZeneca, GlaxoSmithKline, Meda Pharmaceuticals, Merck, Sanofi, UCB, Adamis Pharmaceuticals, Alcon, Alergo Pharma, ALK-Abello, Allergy Therapeutics, Almirall, Ampio, Anergis, Apotex, Ares Life Sciences, Array BioPharma, Aspen Pharmacare, Atopix Therapeutics, Barr Laboratories, Belcher Pharmaceuticals, Circassia Pharmaceuticals, Dainippon Sumitomo, DBV Technologies, Dr Reddy's Laboratories, Eddingpharm, Genentech, Greer Laboratories, Hanmi Pharmaceuticals, Hisamitsu Pharmaceutical, Intas Pharmaceuticals, Kyowa Hakko, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Mylan, Nektar Therapeutics, Novartis, Nuvo Research, Nycomed, Omega Pharma, Ono Pharmaceuticals, Pfizer, Revance Therapeutics, Roxane Laboratories (Boehringer Ingelheim), Shionogi, Stallergenes, Sun Pharmaceuticals, Takeda, Teva Pharmaceuticals, Verona Pharma, VentiRx Pharmaceuticals.